Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of SSGJ-613 in healthy Chinese adults
NCT05966701Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gouty arthritis comparing SSGJ-613 with Placebo (2 arms). Primary endpoint: Adverse events (AEs), measurement of vital signs, physical examination, electrocardiogram and laboratory tests. Status: unknown.
02
Drugs
SSGJ-613
03
Conditions
gouty arthritis
Beyond the preview
Go deeper on NCT05966701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966701.